Ten year longitudinal study of efficacy and safety of purified chick embryo cell vaccine for pre- and post-exposure prophylaxis of rabies in Indian population.

Simple item page
dc.contributor.authorSehgal, Sen_US
dc.contributor.authorBhattacharya, Den_US
dc.contributor.authorBhardwaj, Men_US
dc.date.accessioned1995-03-01en_US
dc.date.accessioned2009-06-01T17:44:41Z
dc.date.available1995-03-01en_US
dc.date.available2009-06-01T17:44:41Z
dc.date.issued1995-03-01en_US
dc.description.abstractOne thousand three hundred and seventy-five (1375) persons, who were vaccinated against Rabies with Purified Chick Embryo Cell (PCEC) vaccine from 1984 to 1993, were included in this ten-year longitudinal study, conducted to observe the consistency, immunogenicity, inocuity, safety and efficacy of PCEC vaccine under controlled trial and field conditions. The study period was divided into three phases. Phases I and II covered the premarketing controlled trial and Phase III the post-marketing serosurveillance study of the vaccine. During Phase I, fifteen healthy volunteers were given a pre-exposure regime of vaccine on Day 0, 7 and 21, and the rest 15, simulated post-exposure regime on Day 0, 3, 7, 14, 30 and 90. All the subjects had satisfactory antirabies antibody response with mean titres, of 7.08 and 5.72 I.U./ml respectively, and minimal side reactions. In the Phase II, from 1984-85, 56 persons with proven rabid animal bites were given post-exposure vaccination and all had satisfactory antibody titres with mean titre of 4.45 I.U./ml after 6th dose of vaccine and with minimal side reactions. 19 to 36 months follow up after vaccination revealed no vaccine failures. In the Phase III post-marketing field study conducted from 1985 to 1993, 1289 persons reported to our Centre for consulation and antirabies antibody titre estimation following PCEC vaccination. One thousand two hundred and fifty-two (1252) persons took post-exposure vaccination following bites by rabid animals, contact with an hydrophobia patient and 37 high risk personnel took pre-exposure vaccination.(ABSTRACT TRUNCATED AT 250 WORDS)en_US
dc.description.affiliationWHO Collaborative Center for Rabies Epidemiology for South-East Asia, National Institute of Communicable Diseases, Delhi, India.en_US
dc.identifier.citationSehgal S, Bhattacharya D, Bhardwaj M. Ten year longitudinal study of efficacy and safety of purified chick embryo cell vaccine for pre- and post-exposure prophylaxis of rabies in Indian population. Journal of Communicable Diseases. 1995 Mar; 27(1): 36-43en_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/111719
dc.language.isoengen_US
dc.subject.meshAdolescenten_US
dc.subject.meshAnimalsen_US
dc.subject.meshAntibodies, Viral --blooden_US
dc.subject.meshChick Embryoen_US
dc.subject.meshChilden_US
dc.subject.meshChild, Preschoolen_US
dc.subject.meshFemaleen_US
dc.subject.meshHumansen_US
dc.subject.meshIndiaen_US
dc.subject.meshInfanten_US
dc.subject.meshLongitudinal Studiesen_US
dc.subject.meshMaleen_US
dc.subject.meshProduct Surveillance, Postmarketingen_US
dc.subject.meshRabies --immunologyen_US
dc.subject.meshRabies Vaccines --immunologyen_US
dc.subject.meshRabies virus --immunologyen_US
dc.subject.meshTime Factorsen_US
dc.titleTen year longitudinal study of efficacy and safety of purified chick embryo cell vaccine for pre- and post-exposure prophylaxis of rabies in Indian population.en_US
dc.typeClinical Trialen_US
dc.typeClinical Trial, Phase Ien_US
dc.typeClinical Trial, Phase IIen_US
dc.typeClinical Trial, Phase IIIen_US
dc.typeJournal Articleen_US
dc.typeMulticenter Studyen_US
Files
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.79 KB
Format:
Plain Text
Description:
Download
Collections
Journal of Communicable Diseases